OTC reshaping gathers momentum

15 December 2014 - Deborah Wilkes

Archived

“Either you eat or you will be eaten” was how Meda’s chief executive officer Dr Jörg-Thomas Dierks summed up the wave of mergers and acquisitions in 2014. During the year, the Swedish company escaped being eaten by US generics company Mylan and then snapped up Italy’s Rottapharm Madaus in its largest transaction to date.

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: